{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:17:47Z","timestamp":1787509067112,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Little information exists on the relationship between bleeding outcomes and physical activity in patients with haemophilia A (PwHA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This interim analysis of the TSUBASA study (UMIN-CTR ID: UMIN000037448) evaluated the association of physical activity with bleeding and safety in PwHA starting emicizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PwHA without factor VIII inhibitors were recruited. Physical activity and bleed data were obtained using an electronic patient-reported outcome application and wearable activity tracker. Adverse events (AEs) were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At data cut-off (31-May-2021), 107 PwHA were enrolled, with a median (range) age of 35 (0\u201373) years. Physical activity data were obtained for 74 participants. Of these, 47 (63.5%) recorded a total of 396 exercise events. The most common exercise events were walking (32.4%), cycling (14.9%), and football (5.4%). Two (0.5%) exercise events in the same individual were associated with bleeding (running, weight training).<\/jats:p>\n                    <jats:p>The safety analysis population consisted of 106 participants treated with emicizumab (median observation period: 241.5\u00a0days). Twenty-one (19.8%) participants experienced a total of 39 AEs. Five (4.7%) experienced a serious AE, none of which was emicizumab-related, and three (2.8%) experienced an adverse drug reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PwHA receiving emicizumab in the TSUBASA study experienced minimal bleeding associated with physical activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Trial registration: UMIN-CTR ID: UMIN000037448.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12185-023-03679-8","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T04:02:22Z","timestamp":1702612942000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiai","family":"Nagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Sugao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"3","key":"3679_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2516.2007.01456.x","volume":"13","author":"A Fromme","year":"2007","unstructured":"Fromme A, Dreeskamp K, Pollmann H, Thorwesten L, Mooren FC, V\u00f6lker K. Participation in sports and physical activity of haemophilia patients. Haemophilia. 2007;13(3):323\u20137.","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"3679_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Elena S, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"1","key":"3679_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1046\/j.1365-2516.2002.00575.x","volume":"8","author":"R Tiktinsky","year":"2002","unstructured":"Tiktinsky R, Falk B, Heim M, Martinovitz U. The effect of resistance training on the frequency of bleeding in haemophilia patients: a pilot study. Haemophilia. 2002;8(1):22\u20137.","journal-title":"Haemophilia"},{"issue":"2","key":"3679_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0031-1286292","volume":"33","author":"JC Souza","year":"2012","unstructured":"Souza JC, Simoes HG, Campbell CS, Pontes FL, Boullosa DA, Prestes J. Haemophilia and exercise. Int J Sports Med. 2012;33(2):83\u20138.","journal-title":"Int J Sports Med"},{"issue":"7","key":"3679_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/MBC.0000000000000565","volume":"27","author":"M Wang","year":"2016","unstructured":"Wang M, \u00c1lvarez-Rom\u00e1n MT, Chowdary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports. Blood Coagul Fibrinolysis. 2016;27(7):737\u201344.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"3679_CR6","first-page":"66","volume":"20","author":"C Biasoli","year":"2022","unstructured":"Biasoli C, Baldacci E, Coppola A, De Cristofaro R, Di Minno MND, Lassandro G, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus. 2022;20(1):66\u201377.","journal-title":"Blood Transfus"},{"issue":"Suppl 4","key":"3679_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/hae.12425","volume":"20","author":"K Fischer","year":"2014","unstructured":"Fischer K, Konkle B, Broderick C, Kessler CM. Prophylaxis in real life scenarios. Haemophilia. 2014;20(Suppl 4):106\u201313.","journal-title":"Haemophilia"},{"issue":"6","key":"3679_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/hae.12485","volume":"20","author":"X Niu","year":"2014","unstructured":"Niu X, Poon JL, Riske B, Zhou ZY, Ullman M, Lou M, et al. Physical activity and health outcomes in persons with haemophilia B. Haemophilia. 2014;20(6):814\u201321.","journal-title":"Haemophilia"},{"issue":"5","key":"3679_CR9","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1111\/j.1365-2516.2011.02555.x","volume":"17","author":"WG Groen","year":"2011","unstructured":"Groen WG, Takken T, van der Net J, Helders PJ, Fischer K. Habitual physical activity in Dutch children and adolescents with haemophilia. Haemophilia. 2011;17(5):e906\u201312.","journal-title":"Haemophilia"},{"issue":"1","key":"3679_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","volume":"28","author":"D Okaygoun","year":"2021","unstructured":"Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28(1):64.","journal-title":"J Biomed Sci"},{"issue":"5","key":"3679_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1542\/peds.2009-0072","volume":"124","author":"C Ross","year":"2009","unstructured":"Ross C, Goldenberg NA, Hund D, Manco-Johnson MJ. Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics. 2009;124(5):1267\u201372.","journal-title":"Pediatrics"},{"issue":"14","key":"3679_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2012.12727","volume":"308","author":"CR Broderick","year":"2012","unstructured":"Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452\u20139.","journal-title":"JAMA"},{"issue":"3","key":"3679_CR13","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1111\/hae.13215","volume":"23","author":"A Iorio","year":"2017","unstructured":"Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017;23(3):e170\u20139.","journal-title":"Haemophilia"},{"issue":"15","key":"3679_CR14","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Emicizumab: a review in haemophilia A. Drugs. 2019;79(15):1697\u2013707.","journal-title":"Drugs"},{"issue":"7","key":"3679_CR15","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","volume":"117","author":"T Kitazawa","year":"2017","unstructured":"Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348\u201357.","journal-title":"Thromb Haemost"},{"issue":"9","key":"3679_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"24","key":"3679_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jimenez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127\u201338.","journal-title":"Blood"},{"issue":"9","key":"3679_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"3679_CR19","doi-asserted-by":"publisher","first-page":"E295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):E295\u2013305.","journal-title":"Lancet Haematol"},{"key":"3679_CR20","unstructured":"Pharmaceutical and Medical Devices Agency. Hemlibra Prescribing Information. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6343451. Accessed Apr 2023."},{"key":"3679_CR21","unstructured":"Health Service Bureau of Ministry of Health Labour and Welfare. Standards for Physical Activity for Health 2013. https:\/\/www.mhlw.go.jp\/stf\/houdou\/2r9852000002xple-att\/2r9852000002xpqt.pdf. Accessed Apr 2023."},{"issue":"8","key":"3679_CR22","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1249\/mss.0b013e3180616b27","volume":"39","author":"WL Haskell","year":"2007","unstructured":"Haskell WL, Lee I-M, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423\u201334.","journal-title":"Med Sci Sports Exerc"},{"issue":"9 Suppl","key":"3679_CR23","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1097\/00005768-200009001-00009","volume":"32","author":"BE Ainsworth","year":"2000","unstructured":"Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9 Suppl):S498-504.","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"3679_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-0031-1275337","volume":"223","author":"K Pierstorff","year":"2011","unstructured":"Pierstorff K, Seuser A, Weinspach S, Laws HJ. Physiotherapy home exercise program for haemophiliacs. Klin Padiatr. 2011;223(3):189\u201392.","journal-title":"Klin Padiatr"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03679-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T11:26:55Z","timestamp":1714562815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03679-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KN: Has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd; personal fees from F. Hoffmann-La Roche Ltd; grants, personal fees and non-financial support from Sysmex Co.; grants and personal fees from Takeda Pharmaceutical Co.; grants and personal fees from Sanofi S.A.; personal fees from CSL Behring Co.; grants and personal fees from KM Biologics Co.; grants and personal fees from Novo Nordisk A\/S; grants and personal fees from Bayer AG; grants and personal fees from Bioverativ Inc; and grants and personal fees from Shire Plc; and is a co-inventor of a patent related to an anti\u2010FIXa\/FX bispecific antibody; TF: Has received speaking and consulting fees from Chugai Pharmaceutical Co., Ltd, Takeda, Sanofi, Novo Nordisk, CSL Behring and JB, and has received research funding from Chugai Pharmaceutical Co., Ltd; AS: Has received speakers\u2019 bureau from Chugai Pharmaceutical Co., Ltd; AN: Has received investigator-initiated grant funding from Takeda (Shire) and Bayer; and honoraria from Sanofi, Takeda, Chugai Pharmaceutical Co., Ltd, Bayer, Fujimoto, KMB, Pfizer, JB, Novo Nordisk, and CSL Behring; CN: Has received speakers\u2019 bureau from Chugai Pharmaceutical Co., Ltd, and Sanofi; MN: Has received advisor fees from Chugai Pharmaceutical Co., Ltd; NS: Has received speaker fees from Chugai Pharmaceutical Co., Ltd, Takeda, Novo Nordisk, CSL Behring, Bayer Yakuhin, Ltd, and Japan Blood Products Organization; DN: Employee of and stockholder in Chugai Pharmaceutical Co., Ltd; TS: Employee of Chugai Pharmaceutical Co., Ltd; YS: Employee of Chugai Pharmaceutical Co., Ltd; KA: Has received consulting fees from Chugai Pharmaceutical Co., Ltd.; has received speakers\u2019 bureau from Bayer, Chugai Pharmaceutical Co., Ltd, CSL Behring, Japan Blood Products Organization, KM Biologics, Novo Nordisk, Pfizer, Sanofi, and Takeda; has received research funding from KM Biologics; and is listed as an entity\u2019s board of directors or advisory committee member for Chugai Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The TSUBASA study is being conducted in compliance with the International Conference on Harmonisation Guidelines for Good Clinical Practice, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and the Declaration of Helsinki. The study protocol was approved by the research ethics committee at each study site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Eligible participants provided informed consent before entering the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}